Will a paper published in The Lancet between April 13–19, 2026 report clinical trial results for a GLP-1 receptor agonist (such as semaglutide or tirzepatide) with a primary endpoint other than weight loss or glycemic control?

A clinical trial paper published in The Lancet (any of its journals) between April 13–19, 2026 features a GLP-1 receptor agonist as the intervention and a primary endpoint that is neither weight loss nor glycemic control (HbA1c or fasting glucose) Source: The Lancet journal website at thelancet.com